I need to check if this filing has sufficient substantive disclosure content (excluding cover pages, boilerplate, signatures, legends, cautionary-language blocks, and exhibit lists). The substantive content here includes the Summary of Material Risks bullets and some financial figures from the cover page (aggregate market value ~$2,982,000, shares outstanding 140,201,055, fiscal year ended July 31, 2026). The body of the 10-K beyond the cover/boilerplate/cautionary statement/table of contents is not included in the extracted text - we only have the cover page, cautionary statement, and the beginning of the risk summary bullets. However, the risk summary bullets and the key financial figures do constitute some substantive disclosure. Let me count the substantive words from the risk summary bullets and cover page financial data - this is borderline but the risk bullets plus financial disclosures likely exceed 150 words. Proceeding with the article based on what is available.

PURE Bioscience, Inc. filed its Annual Report on Form 10-K for the fiscal year ended July 31, 2026, with the SEC on October 29, 2026, disclosing a going concern doubt issued by its auditors and key financial figures for the period.

Key Highlights

  • Going concern doubt: The company disclosed that "our auditors have expressed substantial doubt about our ability to continue as a going concern."
  • Shares outstanding: As of October 29, 2026, there were 140,201,055 shares of common stock, $0.01 par value per share, outstanding, according to the filing.
  • Non-affiliate market value: The aggregate market value of common stock held by non-affiliates was approximately $2,982,000, computed on the basis of the closing price on the OTCQB Bulletin Board on January 31, 2026.
  • Capital needs: The company disclosed it "has limited capital and will need to raise additional capital in the future."
  • Key products: The filing identifies PURE Hard Surface, a food contact surface sanitizer and disinfectant, and PURE Control, a direct food contact processing aid, as the company's food safety product offerings.
  • Smaller reporting company: The registrant is classified as a non-accelerated filer and a smaller reporting company, as indicated in the filing.

PURE Bioscience Reports Auditor Going Concern Doubt in Fiscal Year 2026 Filing

PURE Bioscience, Inc., a Delaware corporation headquartered at 771 Jamacha Rd., #512, El Cajon, California 92019, filed its Annual Report on Form 10-K for the fiscal year ended July 31, 2026, with the SEC. The company's common stock, $0.01 par value, is registered pursuant to Section 12(g) of the Act and trades on the OTCQB Bulletin Board. The filing carries Commission File Number 001-14468. The company noted it operates through itself and its wholly owned subsidiary, ETIH20 Inc., on a consolidated basis.

Among the most prominent disclosures in the filing is the auditors' expression of "substantial doubt about our ability to continue as a going concern," which the company lists as one of the material risks associated with its business. The filing also states that the company "has a history of losses, and we may not achieve or maintain profitability," and that it "has limited capital and will need to raise additional capital in the future." The company cautioned that raising additional funds by issuing securities or through collaboration and licensing arrangements "may cause dilution to existing stockholders, restrict our operations or require us to relinquish proprietary rights," according to the filing.

On the operational side, the filing identifies the need to "continue to increase customer awareness and adoption" of its two main food safety products: PURE Hard Surface, described as "a food contact surface sanitizer and disinfectant designed for restaurant chains, food processors, and transportation companies," and PURE Control, described as "a direct food contact processing aid." The company also acknowledged that it may be unable to correctly estimate future revenues and operating expenses, which could require it to secure additional financing sooner than planned. All forward-looking statements in the filing are the company's own and subject to the cautionary language included in the Annual Report.

What Was Disclosed

PURE Bioscience, Inc. filed a Form 10-K for fiscal year ended July 31, 2026, reporting auditor going concern doubt, approximately $2,982,000 in non-affiliate market capitalization as of January 31, 2026, and 140,201,055 shares outstanding as of October 29, 2026.